XML 98 R2.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Consolidated Balance Sheets - USD ($)
$ in Thousands
Jan. 03, 2020
Dec. 28, 2018
Current assets:    
Cash and cash equivalents $ 266,501 $ 314,775
Short-term investments 585,742 378,559
Trade receivables, net 119,073 162,771
Inventory, net 12,886 9,838
Prepaid expenses and other current assets 26,988 31,073
Total current assets 1,011,190 897,016
Long-term investments 536,385 158,287
Property and equipment, net 48,892 50,897
Deferred tax assets, net 172,374 244,111
Goodwill 63,684 63,684
Other long-term assets 53,145 8,291
Total assets 1,885,670 1,422,286
Current liabilities:    
Accounts payable 11,581 10,901
Accrued compensation and benefits 37,364 32,142
Accrued clinical trial liabilities 38,777 18,231
Rebates and fees due to customers 18,719 14,954
Accrued collaboration liabilities 11,856 7,419
Other current liabilities 24,449 21,825
Total current liabilities 142,746 105,472
Long-term portion of deferred revenue 6,596 15,897
Long-term portion of operating lease liabilities 48,011 12,099
Long-term portion of operating lease liabilities   12,178
Other long-term liabilities 2,347 1,286
Total liabilities 199,700 134,833
Commitments
Stockholders’ equity:    
Preferred stock, $0.001 par value, 10,000 shares authorized and no shares issued 0 0
Common stock, $0.001 par value; 400,000 shares authorized; issued and outstanding: 304,831 and 299,876 at December 31, 2019 and 2018, respectively 305 300
Additional paid-in capital 2,241,947 2,168,217
Accumulated other comprehensive income (loss) 3,069 (701)
Accumulated deficit (559,351) (880,363)
Total stockholders’ equity 1,685,970 1,287,453
Total liabilities and stockholders’ equity $ 1,885,670 $ 1,422,286